KORRO BIO, INC. just moved. Here's exactly what to do next.
Who to reach, what to say, and why now — on KORRO BIO, INC., plus every contract, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).
Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.
Korro Bio Collaborates with Novo Nordisk to Develop Two Therapeutic Candidates
Contract Type
partnership
CambridgeDescription
Korro Bio, Inc. has announced a partnership with Novo Nordisk to advance the discovery and development of new genetic medicines, with the initial target to treat cardiometabolic diseases. The collaboration aims to leverage Korro’s proprietary OPERATM platform to enable oligonucleotide-directed RNA edits into two undisclosed targets, with a total deal value of up to $530 million in upfront, development, and commercial milestone payments, in addition to tiered royalties and R&D funding.